Ah‐Reum Jeong

Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL

Phil Yeung, Aaron Trando, Ah‐Reum Jeong, Dimitrios Tzachanis

Background/Objectives: CAR T-cell therapy is a highly efficacious therapy option for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but its widespread use is currently limited by safety concerns and high healthcare costs. Methods: We evaluated 66 patients with R/R LBCL treated with tisagenlecleucel …

us (code pays fourni par la source)

Evaluating Healthcare Provider and Artificial Intelligence Chatbot Responses to Patient Messages from a Health System Using the CREATE TRUST Framework

Matthew R. Allen, Vijay M. Tiyyala, Armaan Johal, Akhila Chekuri et autres

Integration of artificial intelligence chatbots into healthcare requires rigorous, patient-centered evaluation. This study implements the CREATE TRUST framework-a novel tool evaluating both clinical substance and communication style-to compare responses from healthcare providers (HCPs) and two AI chatbots (GPT-4, Mixtral) to complex clinical …

us (code pays fourni par la source)

Refractory Periorbital Necrobiotic Xanthogranuloma Treated With Plasma Cell‐Directed Therapy

Aaron Trando, Ah‐Reum Jeong, Aaron Michael Goodman

A 57-year-old female with a reported history of isolated neutropenia presented with 3 years of progressive bilateral vision loss and 4 months of a rapidly growing plaque on her FIGURE 1 Physical examination demonstrated necrobiotic xanthogranuloma skin lesions of the patient's left …

us (code pays fourni par la source)

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma

Yosra M. Aljawai, Ah‐Reum Jeong, Muthalagu Ramanathan, Gunjan L. Shah et autres

Abstract Background and Significance Autologous hematopoietic cell transplant (AHCT) is standard of care for multiple myeloma (MM) treatment, following induction therapy. Adequate mobilization and number of infused hematopoietic progenitor cells (HPCs) is associated with engraftment and survival outcomes. The increased use of …

us, gb (code pays fourni par la source)

Long-term follow-up of novel post-transplant cyclophosphamide (PTCy) and abatacept (aba) graft-versus-host disease (GVHD) prophylaxis regimen compared to tacrolimus and methotrexate.

Kaitlyn C. Dykes, Divya T. Koura, Aaron Michael Goodman, Caitlin L. Costello et autres

Abstract Introduction: Advances in relapse and GVHD prevention have led to improved effectiveness and safety of allogeneic hematopoietic cell transplantation (HCT) over the decades, thus making allogeneic HCT a potentially curative possibility for more patients. Unfortunately, despite improved long-term survival, both relapse …

us (code pays fourni par la source)

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

Swaminathan P. Iyer, Salvia Sanjay Jain, Aaron M. Goodman, Julie Marie Vose et autres

Abstract Introduction: There are few effective treatments for patients (pts) with relapsed/refractory T-cell lymphoma (R/R TCL). One challenge in targeting T-lineage antigens is the risk of ablating normal T cells. MB-105 is a CD5-directed CAR T-cell product that resists self-targeting through rapid …

us (code pays fourni par la source)

Exploring co-mutations in CML and ph(+) b-ALL with ABL1 variants: Correlations with survival and treatment response.

Kaitlyn C. Dykes, Nicholas J. Protopsaltis, James K. Mangan, Caitlin L. Costello et autres

Abstract Introduction The impact of co-mutations seen with ABL1 kinase domain mutations is unclear in today's treatment landscape (Branford 2024). We conducted a retrospective study to explore the relationship between ABL1 variants and other co-mutations. Methods This study was exempt from IRB …

us (code pays fourni par la source)

A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept

Divya T. Koura, Kaitlyn C. Dykes, Aaron Michael Goodman, Caitlin L. Costello et autres

ABSTRACT: We conducted a prospective randomized clinical trial to investigate the combination of posttransplant cyclophosphamide (PTCy) and abatacept (Aba) for graft-versus-host disease (GVHD) prophylaxis. Patients with hematologic malignancies undergoing an allogeneic transplant from an 8/8 matched related or unrelated donor were randomized …

us (code pays fourni par la source)

796 | SERUM AND DEEP‐LEARNING‐BASED MRI BIOMARKERS OF NEUROTOXICITY AND SURVIVAL IMPLICATIONS AFTER CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY IN NON‐HODGKIN LYMPHOMA

Aisong Zhu, J. Rudie, Rohit Saluja, Parag R. Sanghvi et autres

were associated with decreased risk.The previously reported association of mEASIX with CRS/ICANS was less pronounced in our models.We plan to confirm these results in an independent validation cohort with additional predictors.

us (code pays fourni par la source)

453 | EFFICACY AND TOXICITY OF RADIATION THERAPY PRIOR TO CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

K. Daniels, Collin M. Costello, Ah‐Reum Jeong, P. Sangvhi et autres

us (code pays fourni par la source)

835 | A MULTICENTER, OPEN‐LABEL, Ph 1 STUDY TO ASSESS THE SAFETY OF P‐CD19CD20‐ALLO1, AN ALLOGENEIC CAR‐T CELL THERAPY, IN SUBJECTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

Taha Mahdi Salih Al-Juhaishi, Bhumika J. Patel, Natalie Sophia Grover, Holly E. Holmes et autres

A preliminary analysis of data on 250 ex-patients has been planned and enrollment is expected to be completed in 18 months.This study will lead to the validation of a specific LS-SCP model for patients treated for lymphoma between the ages of 18 …

us (code pays fourni par la source)

A novel application of deep learning (DL)-based MRI with liquid biomarkers for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor (CAR) T-cell therapy.

Kathryn Ries Tringale, Caitlin L. Costello, Rachit Saluja, Jeffrey D. Rudie et autres

2516 Background: ICANS is a complication of CAR T-cell therapy, yet risk factors and quantitative diagnostic criteria, particularly neuroimaging criteria, remain incompletely characterized. We implemented a novel application of a deep learning (DL)-based MRI approach alongside clinical and liquid biomarkers to better …

us (code pays fourni par la source)